Over the years, comScore has published several studies – including one this past week – that illustrate how the click is often the wrong metric for measuring the effectiveness of online display advertising.
S'appuyant la masse extraordinaire de données issue des objets connectés de santé, des réseaux sociaux et du séquençage génomique, le big data appliqué à la santé apparait comme le nouvel eldorado des laboratoires pharmaceutiques.
Optimiser les essais cliniques, personnaliser les traitements et accompagner les patients, réduire les coûts de la R&D... ce nouveau marché s'annonce aussi prometteur médicalement qu'économiquement.
Mais les big pharma ne le conquerront pas sans les géants du web et les start-up biotech.
Biogen disclosed in its first-quarter earnings report that it has been subpoenaed by the federal government. The subpoena requests documents detailing its relationship with nonprofit foundations that assist patients taking drugs sold by the company. These foundations often provide financial support to patients who cannot afford their medications. Biogen said it is cooperating with the government inquiry.
It is illegal for drugmakers to give patients copay assistance if they are insured by federally funded healthcare programs. Some drugmakers fund outside foundations that, in turn, direct money towards patients for medications. These foundations are bound by rules that dictate the terms of this assistance; the foundations, for example, cannot restrict coverage to only one drug.
Patient-assistance programs have come under fire in recent months. During a House hearing, Rep. Eleanor Holmes Norton (D-DC) charged Turing Pharmaceuticals with using patient-assistance programs as a means of diverting attention from the high price of the company's toxoplasmosis treatment, Daraprim. Some critics contend that drugmakers create the need for patient-assistance programs by pricing their drugs too high.
Global Study Reveals Only Five Percent of Health Organizations Excel at Digital Innovation
While health organizations are actively experimenting with digital technologies, many lack the expertise and resources to implement and scale these innovations optimally
This research reveals that:
- Only 5% of health organizations are operating at the highest level of digital health innovation proficiency and expertise
- The majority of organizations globally are in the digital health pilot testing and experimentation phase
- Progress is slow even in relatively mature technology areas such as social media and mobile
- Organizations do not yet have sufficient technical expertise or budgetary resources to efficiently scale their innovation efforts
European Commission - Press Release details page - European - Press release Commission Brussels, 19 April 2016 Delivering on its Strategy to create a Digital Single Market, the Commission today unveiled its plans to help European industry, SMEs, researchers and public authorities make the most of new technologies. The European Commission today presented a set of measures to
Biogen CEO George Scangos told investors the company's direct-to-consumer advertising campaign for its multiple-sclerosis drug Tecfidera was designed to address “low awareness” for the drug.
“We were surprised, actually, at the beginning by the low awareness among patients of Tecfidera,” Scangos said during Biogen's first-quarter earnings call Thursday, “and we had data suggesting that when patients did learn about Tecfidera and went to their physician to discuss it, they often had it prescribed.”
He added that the ad “did succeed” in raising awareness about Tecfidera even though the drug's sales missed analysts' estimates for the quarter. Tecfidera brought in sales of $744 million for the first quarter of 2016, missing analysts estimates of $750 million, however sales are still up 12% from the $648 million the drug brought in during the first quarter of 2015. However, compared to last quarter, Tecfidera sales are down 5%.
Scangos would not say whether that heightened awareness from the DTC campaign translated into more sales. He said the drugmaker plans to give investors an update on the campaign during its next quarterly earnings call.
Low awareness of Tecfidera is surprising given the warm reception it received from neurologists even before the drug had become available, according to a poll conducted by WorldOne Interactive.
[It's also surprising given the hype about how social media mentions predicted great sales. For more on that, read "Using Social Media as an Early Predictor of a New Drug's Market Share"; http://bit.ly/Mantelconvo]
More and more, pharma companies are making real bets in digital health, and reorganizing their businesses to put some power behind those efforts. The space is, in some ways, quieter than it was this time last year, but there’s reason to believe that quiet is a calm before a storm of activity, driven more by pharma’s tendency to keep early-stage projects close to the chest than by a lack of activity.
Twitter generates 1.5 percent of traffic for typical news organizations, according to a new report from the social analytics company Parse.ly that examined data from 200 of its client websites over two weeks in January. (You'll need to give Parse.ly your email address to access the full report.) Pa…
L'asbl FeBelGen, qui regroupe les sociétés de médicaments génériques et biosimilaires établies en Belgique, affirme que les médicaments biosimilaires sont "nécessaires pour conserver des soins de santé abordables". Ceux-ci, souvent moins chers que le prix initial du médicament biologique original, permettraient des économies dans le budget de l'assurance maladie-invalidité Inami. Celle-ci pourrait alors financer de nouveaux médicaments biologiques, encore protégés par leur brevet.
Merck & Co will no longer file for approval of once-weekly diabetes drug omarigliptin in the US or Europe.
The company said in a statement that the decision did not relate to any safety or efficacy issues with the DPP-4 inhibitor, which might suggest it is not confident that the market is prepared to pay a premium for a weekly compared to a once-daily drug such as Merck's own Januvia (sitagliptin) product.
There are thought to be other issues with once-weekly administration of DPP-4 inhibitors. While they are intended to reduce the burden of taking pills by diabetics and improve compliance, patients can rarely benefit from drug-free days as those on DPP-4 inhibitors often also take metformin, which must be dosed every day.
Some clinicians argue that it is easier for patients to keep track of dosing two drugs side by side rather than mixing weekly and daily doses.
Boehringer Ingelheim BI) is leading the pharma industry in posting disease awareness videos on Youtube. Several focus on cardio-respiratory conditions such ad COPD. See, for example, "2 SIDES OF LIVING WITH COPD," which I said "Tugs at Heart Strings, Then Scares the Bejeezus Out of Us! Is it necssary to pull at our heart strings and then bring us down with scary death mask-like imagery?"
Well, if you thought that video was scary, you might "shi* your pants" watching "How does it feel to live with IPF?", which is an even scarier, disease awareness video from BI.
IPF is shorthand for Ideopathic Pulmonary Fibrosis - a disease in which tissue deep in the lungs becomes thick and stiff, or scarred, over time. It usually affects middle-aged and older adults. BI markets OFEV for treating IPF. You can find more information on IPF and results from a BI survey here.
The dark image of a woman starring off into the dark sky was captured from the video, which you can see here. Why always women?
But there's something even odder, more ominous about this video. More...
Sanofi lance une campagne nationale de sensibilisation à l’hypercholestérolémie familiale qui débute à partir du 15 avril avec la mise en ligne du site web aucoeurducholesterol.fr. Menée conjointement avec les associations de patients ANHET.F et Alliance du Coeur, elle a pour objectif de sensibiliser le grand public et les professionnels de santé à cette maladie silencieuse peu connue en France.
Développé par Sanofi, le site www.aucoeurducholesterol.fr est une plateforme d’information et d’accompagnement des patients à haut risque cardiovasculaire et dont le taux de LDL-C est élevé. Ce site propose une section entièrement dédiée à l’hypercholestérolémie familiale, et qui permettra au grand public, concerné ou pas, d’accéder facilement à des informations sur l’hypercholestérolémie familiale, sur ses conséquences, son diagnostic ainsi que sur l’importance du dépistage familial en cascade.
Cette campagne se déclinera également sur différents supports : presse, campagne d’affichage dans les salles d’attentes des cabinets médicaux et des laboratoires d’analyses mais également sur les canaux digitaux. Par ailleurs, des vidéos d’experts et des témoignages de patients seront mis en ligne sur la chaine Youtube de Sanofi France. Un film, Heartfelt, relatant, à travers le monde, des histoires de vie de patients atteints d’un taux de LDL-élevé, sera aussi mis en ligne.